Thursday, November 19, 2026 Updated Briefings Saved 中文
AI Daily Radar

AI and the frontier tech around it, explained every morning

Released

FDA approves Roche's giredestrant for ESR1-mutated breast cancer

Photo: stevepb / Pixabay

The FDA on Monday approved Roche’s giredestrant, marketed as Wilserdly, for patients with HR-positive, HER2-negative advanced breast cancer whose tumors carry an ESR1 mutation. The approval covers an oral selective estrogen receptor degrader (SERD) for a population in which that mutation is a sign of resistance to standard treatment. STAT reported that Roche’s evERA trial showed the drug extended the time before tumors progressed, but the available excerpt was truncated before full efficacy, safety, pricing, or launch details. Roche has said the medicine could become its top-selling product ever, a company claim rather than an independent forecast.

Verified and unconfirmed

  • Verified: STAT reports that the FDA approved giredestrant (Wilserdly) on Monday for HR-positive, HER2-negative advanced breast cancer with an ESR1 mutation, based on the evERA trial, which showed a longer period before tumor progression.
  • Not yet confirmed: The size of that progression-free survival benefit, overall survival or safety data, price, and launch timing were not in the available excerpt; Roche’s claim that the drug could be its top-selling product ever is a company assertion, not an independent estimate.

Background

Giredestrant belongs to a class called selective estrogen receptor degraders (SERDs), which break down the estrogen receptor rather than merely blocking it — a distinction that matters once a tumor picks up an ESR1 mutation and stops responding to standard endocrine therapy. The approval rests on the phase 3 evERA trial, which Roche and its Genentech subsidiary reported on Sept. 30, 2026: the study compared giredestrant plus everolimus with a physician’s choice of endocrine therapy plus everolimus in ER-positive, HER2-negative locally advanced or metastatic breast cancer. Genentech said at the time that the FDA had accepted its New Drug Application for that combination in ESR1-mutated patients whose disease had recurred during or after endocrine treatment.

Why it matters

Eligible patients gain an oral SERD option after their tumors develop an ESR1 mutation, but clinicians will need ESR1 testing to identify who qualifies.

What to watch

Watch for Roche’s launch and U.S. pricing announcement for Wilserdly, and for fuller evERA trial results beyond the progression-free survival finding cited in the approval report.

Further reading

Comments

Comments

Comments use a GitHub account and are moderated. Comment rules

More in Science & Biotech

See all